As the evidence requirements of payers and regulators continue to converge, data collection solutions like chart review studies ... outcomes impact of a novel therapy, or formulation, once it ...

and Services PMI holding steady at 49.3. German data is projected at 42.7 for manufacturing and 51.1 for services. ECB President Lagarde’s speech later today could provide further policy ...

Ultragenyx (RARE) Pharmaceutical announced new data demonstrating treatment with UX111 AAV gene therapy led to a statistically significant improvement in the Bayley-IIIi raw scores for the ...

Sangamo Therapeutics (NASDAQ:SGMO) reported positive updated data from a Phase 1/2 study of its gene therapy candidate isaralgagene civaparvovec, or ST-920, in the treatment of Fabry disease.

Benitec Biopharma Inc. (NASDAQ: BNTC), a clinical-stage biotechnology company with a market capitalization of $225 million, announced today that it will present interim data from its ongoing Phase ...

One of the most notable additions is Gemini's ability to generate graphs based on spreadsheet data. Users can instruct the AI to create visual representations, such as a chart of segments by ...

Last August, Tris Pharma commenced two pivotal Phase III studies, ALLEVIATE-1 and ALLEVIATE-2, to assess the therapy. "Tris Pharma reports positive data from Phase III acute pain therapy trial ...

Still, he spent much more of the speech talking about U.S. AI commitments and didn't mention digital assets again. The sector will likely be watching closely at 2:30 p.m. Eastern on Thursday ...

Monday marked a new chapter in American history as President Donald J. Trump delivered his powerful inaugural address, setting forth a bold vision for our nation's future. Speaking from Washington ...

"From this moment on, America's decline is over," he said. Watch Mr. Trump's speech in the player above.

Following the interim analysis, the company said REGAL’s Independent Data Monitoring Committee has ... choice of the best available therapy in AML patients who are in second or later complete ...